Hepatoprotective Function Evaluation Experiment: Methods, Standards, and Applications

The hepatoprotective function evaluation experiment is a standardized in vivo testing program used to verify whether health foods, functional ingredients, or pharmaceutical candidates can protect the liver against chemically or alcohol-induced injury. By integrating serum biochemistry, antioxidant capacity assays, hepatic lipid analysis, and histopathological examination in validated rodent models, this experiment delivers authoritative scientific evidence for product registration, functional claim substantiation, and research and development optimization.

Technical Overview

The hepatoprotective function evaluation experiment is a systematic in vivo assessment designed to determine whether a test substance can prevent or alleviate liver damage caused by hepatotoxic agents. As the central organ of metabolism, detoxification, and protein synthesis, the liver is a primary target for functional intervention, making rigorous efficacy verification essential before any liver-protection claim can be made for a commercial product.

The experiment is generally conducted in accordance with nationally recognized health food function evaluation procedures and the GB 15193 series of food safety toxicological testing standards, within animal facilities operated under Good Laboratory Practice principles and laboratory animal welfare requirements consistent with OECD guidance. The core scientific logic is straightforward: the test substance is orally administered to rodents at multiple dose levels for a defined period, an acute or subacute liver injury is then induced using a validated hepatotoxin, and the treated animals are compared with untreated injured controls across biochemical, antioxidant, lipid, and histopathological endpoints. A positive hepatoprotective effect is concluded only when statistically significant improvement is demonstrated in both serum biochemical indicators and liver pathology, ensuring that the conclusion is robust and defensible in regulatory review.

Testing Samples

Health Foods and Finished Dietary Supplements

Finished products intended to carry a liver-protection or chemical liver injury protection claim, including tablets, hard capsules, softgels, granules, oral liquids, powdered beverages, and functional teas. The product should be tested in its final market form or as a representative batch of the commercial formulation.

Functional Ingredients and Natural Bioactive Compounds

Raw materials and active constituents intended for functional product development, such as plant extracts, flavonoids, polyphenols, polysaccharides, silymarin-type compounds, fermentation products, protein hydrolysates, and probiotic preparations. Ingredient-level testing helps formulators screen candidates before committing to full product development.

Novel Foods, Traditional Formulations, and Preclinical Drug Candidates

Novel food ingredients, traditional medicine formulations, botanical drug candidates, and lead compounds in preclinical development may also be evaluated using the same experimental framework to support registration dossiers, patents, and scientific publications.

Typical sample submission requirements include sufficient material for all dose groups throughout the administration period, along with documentation of composition, recommended human daily intake, physical and chemical properties, and storage conditions.

Testing Items

A comprehensive hepatoprotective evaluation covers the following categories of indicators:

• Serum liver function enzymes: alanine aminotransferase (ALT/GPT), aspartate aminotransferase (AST/GOT), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT).
• Synthetic and excretory function: total protein (TP), albumin (ALB), and total bilirubin (TBIL).
• Hepatic lipid metabolism: triglyceride (TG) and total cholesterol (TC) content in liver tissue homogenate.
• Antioxidant system status: superoxide dismutase (SOD) activity, reduced glutathione (GSH) content, glutathione peroxidase (GSH-Px) activity, and malondialdehyde (MDA) level as a lipid peroxidation marker.
• Histopathological examination: hematoxylin-eosin (HE) staining of paraffin sections with blinded scoring of hepatocellular ballooning, fatty degeneration, necrosis, and inflammatory infiltration; Oil Red O staining of frozen sections for hepatic steatosis where applicable.
• General observations: body weight trajectory, food and water intake, organ weight, liver index (liver-to-body weight ratio), and clinical signs throughout the study.

Testing Methods

Experimental Design and Animal Grouping

Healthy adult SPF-grade mice (typically 18–22 g) or rats (typically 150–200 g) are randomly assigned to a blank control group, an injury model control group, a positive reference group, and three dose groups of the test substance. Doses are commonly designed at 5-fold, 10-fold, and 30-fold multiples of the recommended human daily intake, converted on a body surface area basis. The test substance is administered daily by oral gavage or dietary admixture for a period of typically 30 days, or longer for lipid- and metabolism-oriented models. All procedures are executed under institutional animal ethics approval and quality management systems consistent with GLP requirements.

Carbon Tetrachloride-Induced Liver Injury Model

The carbon tetrachloride (CCl4) model is the classical chemical liver injury paradigm. CCl4 is bioactivated by hepatic cytochrome P450 enzymes into trichloromethyl free radicals, which trigger lipid peroxidation, membrane disruption, and centrilobular hepatocellular necrosis. Following the administration period, a single challenge dose of CCl4 in oil vehicle is delivered intraperitoneally or subcutaneously, and biological samples are collected 16 to 24 hours later in mice or 24 to 48 hours later in rats, capturing the peak window of enzymatic release and pathological change.

Alcohol-Induced Liver Injury Model

This model replicates the early stages of alcoholic liver disease. Animals receive ethanol by gavage at a defined concentration and volume, or are maintained on an alcohol-containing liquid diet, after which serum transaminases, hepatic triglyceride accumulation, and steatosis grading are assessed. It is the preferred model for products positioned around alcohol metabolism support and defense against alcoholic fatty liver.

D-Galactosamine-Induced Liver Injury Model

D-galactosamine produces diffuse hepatic necrosis and inflammatory changes that closely resemble viral hepatitis, making this model suitable for evaluating interventions aimed at hepatitis-like injury and general hepatocellular protection.

Additional and Specialized Models

Depending on the product positioning, accredited third-party laboratories can also deploy acetaminophen (APAP) overdose models for drug-induced liver injury, thioacetamide (TAA) models for fibrosis-prone injury, and high-fat diet models for non-alcoholic fatty liver disease, extending the evaluation to chronic and metabolic liver pathology.

Biochemical and Histopathological Analysis

Serum markers are quantified on automated clinical chemistry analyzers using validated reagent systems. Liver tissue is homogenized for hepatic TG, TC, and antioxidant parameter determination by spectrophotometric methods. For pathology, liver lobes are fixed in neutral formalin, processed into paraffin sections, stained with HE, and scored by qualified veterinary pathologists under blinded conditions. Statistical comparison among groups is performed using appropriate parametric or non-parametric tests.

Result Judgment Criteria

• Serum ALT and/or AST levels in the dose groups are significantly lower than those of the injury model control group.
• Hepatic TG, TC, MDA levels decrease significantly, or SOD, GSH, GSH-Px levels increase significantly relative to the model control.
• Histopathological lesion scores for degeneration, necrosis, or steatosis are significantly alleviated compared with the model control.
• No adverse effect on body weight, food intake, or general condition is observed, confirming the result reflects protection rather than toxicity masking.
• A positive hepatoprotective conclusion generally requires concordant improvement in at least one serum biochemical indicator together with supporting hepatic parameter or pathology evidence.

Applications

Hepatoprotective function evaluation experiments serve a wide range of commercial and scientific purposes:

• Registration and filing support for health foods seeking approved liver-protection function claims in jurisdictions requiring substantiating in vivo data.
• Functional claim substantiation for dietary supplements, functional beverages, and nutraceutical products entering domestic or international markets.
• Efficacy screening and dose-response optimization during research and development, enabling informed selection of active ingredients and formulation ratios.
• Mechanistic investigation of antioxidant, membrane-stabilizing, and lipid-metabolism-modulating pathways underlying the observed protection.
• Technical support for patents, scientific publications, product monographs, and marketing materials requiring credible experimental evidence.
• Quality benchmarking of raw material suppliers by comparing hepatoprotective potency across batches or sources.

FAQ

Which animal model should be selected for my product?

The model should match the product positioning. The CCl4 model is the general standard for chemical liver injury claims, the alcohol model suits products targeting drinking scenarios and alcoholic fatty liver, the D-galactosamine model addresses hepatitis-like injury, and high-fat diet models apply to fatty-liver-oriented formulations. Laboratory scientists can recommend the most appropriate design after reviewing the product profile.

How long does a complete evaluation take?

A typical study, including acclimation, a 30-day administration period, injury induction, sample collection, biochemical and pathological analysis, and report issuance, generally requires six to ten weeks depending on the model and evaluation scope.

What sample quantity and information are required?

Applicants typically provide sufficient material to cover all dose groups for the full administration period, commonly several hundred dosage units or one to two kilograms of bulk material, together with the composition sheet, recommended human daily intake, and relevant physicochemical specifications.

What constitutes a positive result?

A positive conclusion requires statistically significant improvement over the injury model control in serum transaminase levels, supported by corresponding improvement in hepatic lipid, antioxidant, or histopathological endpoints, with no confounding adverse effects on the animals.

Under what quality framework are the studies performed?

Reputable accredited third-party laboratories conduct these evaluations under GLP-aligned quality management systems, national health food function evaluation technical procedures, and the GB 15193 series standards, with animal work reviewed and approved by institutional ethics committees in compliance with OECD-consistent welfare principles.